Abbott’s Device And Diagnostics Businesses Maintain Growth Momentum In Q1
Abbott appears well-positioned to weather the pandemic with continued revenue growth in diabetes, heart failure devices and molecular diagnostics.
You may also be interested in...
Abbott Sees Signs Of Post-Pandemic Recovery In Q2
Abbott’s medical device sales were down about 20% year-over-year in the second quarter of 2020, but diagnostics sales were up 7%. Procedure trends at the end of the second quarter suggest that demand for devices will soon recover to pre-pandemic levels.
FDA Clears Medtronic's And Boston Scientific's Remote Cardiac Monitors, Approves Abbott’s Bluetooth-Compatible ICDs
Medtronic will launch the LINQ II remotely programmable, insertable cardiac monitor in the US and Europe this summer following FDA clearance. Boston Scientific plans to launch its LUX-Dx monitor later this year. The agency also approved Abbott's Gallant ICD and CRT-D devices, which communicate with Abbott's myMerlinPulse mobile app.
CMS Proposes Coverage Policy For Transcatheter Edge-to-Edge Mitral Valve Repair
In a new draft National Coverage Determination, the US Medicare agency proposes extending coverage of transcatheter mitral valve repair to certain patients with functional mitral regurgitation.